Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
Is a |
difteri- + tetanus- + kighoste- + rekombinant hepatitis B-virus-vaccine |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
rekombinant vaccine mod hepatitis B-virus |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
difterivaccine |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
kighostevaccine |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
tetanustoxoid |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
Has manufactured dose form |
injektionsvæske |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Diphtheria toxoid |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
tetanusvaccine |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Diphtheria vaccine |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
Is a |
Product manufactured as parenteral dose form (product) |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
Has manufactured dose form |
Solution for injection |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
Is a |
TEMPORARY parent for CDs that are not updated |
false |
Inferred relationship |
Some |
|
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
kighostevaccine |
false |
Inferred relationship |
Some |
3 |
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
tetanusvaccine |
false |
Inferred relationship |
Some |
4 |
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Diphtheria vaccine |
false |
Inferred relationship |
Some |
2 |
|
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
rekombinant vaccine mod hepatitis B-virus |
false |
Inferred relationship |
Some |
1 |
|